Type 2 Diabetes – Pipeline Insight, 2026

DelveInsight’s “Type 2 Diabetes – Pipeline Insight, 2026” report provides comprehensive insights about 75+ companies developing 80+ pipeline drugs in the Type 2 Diabetes pipeline landscape. It covers the Type 2 Diabetes pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Type 2 Diabetes treatment landscape. Learn more about the evolving Type 2 Diabetes pipeline today @ https://www.delveinsight.com/sample-request/type-2-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Type 2 Diabetes Pipeline Report

• On March 05, 2026, Eli Lilly and Company initiated a Phase 3 study to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control.

• On March 03, 2026, AstraZeneca announced a Phase II study, a randomized, parallel group, double-blinded, placebo-controlled, multicenter trial, to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and Type 2 Diabetes on stable GLP-1 RA therapy.

• DelveInsight’s Type 2 Diabetes Pipeline Insight report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Type 2 Diabetes treatment.

• The leading Type 2 Diabetes companies include Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and others.

• Promising Type 2 Diabetes therapies include Empagliflozin, Subetta, AZD6234, AZD1656, Glipizide, iGlarLixi (insulin glargine/lixisenatide), GFT505 80mg, Pioglitazone, Metformin, Sulfonylurea, and others.

Download for updates and the latest revolution in Type 2 Diabetes care @ Type 2 Diabetes Clinical Trials Assessment

Type 2 Diabetes Emerging Drugs Profile

• XW014: Sciwind Biosciences XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for the treatment of obesity and Type 2 Diabetes (T2D). XW014 functions as a GLP-1 receptor agonist, mimicking the action of the GLP-1 hormone released after meals. This hormone plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. As an oral small molecule, XW014 offers advantages over traditional peptide-based GLP-1 therapies, such as ease of administration and the potential for combination use with other oral medications. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Type 2 Diabetes.

• KN056: Suzhou Alphamab Co., Ltd. KN056 is a glucagon-like peptide-1 receptor (GLP-1R) modulator developed by Suzhou Alphamab Co., Ltd. KN056 targets the GLP-1 receptor — a key regulator of glucose metabolism that stimulates insulin secretion, inhibits glucagon release, and promotes satiety. By modulating the GLP-1 receptor, KN056 aims to improve glycemic control in patients with Type 2 Diabetes. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Type 2 Diabetes.

For more information on the Type 2 Diabetes Emerging Drugs Profile, download DelveInsight’s comprehensive Type 2 Diabetes Pipeline Insight report.

The Type 2 Diabetes Pipeline Report Provides

• Detailed insights about companies developing therapies for Type 2 Diabetes, with aggregate therapies developed by each company.

• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Type 2 Diabetes treatment.

• Type 2 Diabetes companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Type 2 Diabetes drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company–company and company–academia), licensing agreements, and financing details for future advancement of the Type 2 Diabetes market.

Learn more about Type 2 Diabetes drug opportunities in our comprehensive Type 2 Diabetes pipeline report @ Type 2 Diabetes Unmet Needs

Type 2 Diabetes Companies

There are 75+ key companies, such as Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and others, developing therapies for Type 2 Diabetes, with Eli Lilly and Company having its Type 2 Diabetes drug candidate in the most advanced Phase III stage.

DelveInsight’s Type 2 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Parenteral

• Intravenous

• Subcutaneous

• Oral

• Tropical

Type 2 Diabetes products have been categorized under various Molecule types such as:

• Gene Therapy

• Monoclonal antibody

• Peptides

• Polymer

• Recombinant protein

• Small molecule

Discover the latest advancements in Type 2 Diabetes treatment by visiting our website. Stay informed @ Type 2 Diabetes Market Drivers and Barriers, and Future Perspectives

Scope of the Type 2 Diabetes Pipeline Report

• Coverage: Global

• Type 2 Diabetes companies: Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and others

• Type 2 Diabetes Therapies: Empagliflozin, Subetta, AZD6234, AZD1656, Glipizide, iGlarLixi (insulin glargine/lixisenatide), GFT505 80mg, Pioglitazone, Metformin, Sulfonylurea, and others

• Type 2 Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Type 2 Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Table of Contents

1. Introduction

2. Executive Summary

3. Type 2 Diabetes: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Type 2 Diabetes – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Mid Stage Products (Phase II)

9. Early Stage Products (Phase I)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Type 2 Diabetes Key Companies

13. Type 2 Diabetes Key Products

14. Type 2 Diabetes Unmet Needs

15. Type 2 Diabetes Market Drivers and Barriers

16. Type 2 Diabetes Future Perspectives and Conclusion

17. Type 2 Diabetes Analyst Views

18. Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services